The State Council, Shanghai New Deal Positive Biomedical Drugs Will Industrializ
These days, Shanghai Ellis Medicine Technology Co., Ltd. is busy around for the new drug production sites. This year in March, the company independently developed the first Sartan my blood pressure medication, “Eric losartan” into clinical trials, production is expected early next year to get approval to buy land and build factories imminent.
Now in Shanghai, are busy putting the card into a pharmaceutical drug companies, far more than Ellis 1. Reporter learned yesterday from the Municipal Science and Technology Commission, the next three years, Shanghai is a class will have 48 new drugs in succession to play “paid off” into the critical period of industrialization; the same time there will be a large variety of medical needs of hundreds of process optimization , upgrading the quality of secondary development.
Identified as the latest high-tech industrial city of one of the nine priority areas, Shanghai biomedical industry is in the new round of development of “critical juncture” on. Therefore, the Municipal Science and Technology Commission specifically took out 120 million yuan to set up transformation of biomedical industry programs focused on helping companies form a production capacity.
For Ellis such as R & D enterprise, once Eric losartan successful industrialization, it means the company from a purely qualitative change into high-yield. “We intend to enclosure of 100 acres, the construction of production lines 4-6, the initial investment is expected to require from 200 million to 300 million yuan. At this point, if helping the Government can not only ease the financial pressure to some extent, but will strengthen business confidence. “Ellis Xiao-fang, director of corporate strategic development environment for the growth of new drugs promising.
Occupy the global 1 / 4 AIDS API Medicine on the market Haidisainuo Investment Co., Ltd., the output value reached 1.5 billion last year. After several years of rapid expansion, this was originally intended to moderate contraction, control risk. I heard recently introduced industrial incentive policy, the company decided to invest 130 million yuan, the annual production capacity of 1 billion Zhangjiang Xing AIDS drug product production line. Jin-liang, chairman admitted, for the siting of new production lines, there had been disputes within the company, after all, Shanghai’s relatively high labor and operating costs. “A few days ago, the biomedical industry’s favorable policies are introduced, we scrap the idea to plant the field, confidence is more important than money!”
In the global Financial The context of economic crisis, bio-pharmaceutical industry has become a city one of the few Nifengfeiyang industries. Last year, the city’s biomedical industry, total economic output reached 103.46 billion yuan, up 15.8%. In the first 4 months, the industry still maintained a rapid growth of 15%. Into the city’s 410 biomedical statistical enterprises, the existing value of more than 200 million yuan of 38 leading businesses and 45 years Sell Value exceeds 100 million yuan of competitive products. However, compared with the advantages of Shanghai R & D, biomedical industry is still more room for future development.
Despite the worry about sales, market has been 28 years of HMP has always maintained a pioneering idea. Since 2001, the grain diameter of only 2.85 mm of pills has gone through four or five large and small technology innovations, sales jumped from 6,000 million to 270 million yuan last year. “Peeling layers of bamboo”, is the “old” Traditional Chinese medicine Bigger market recipe for success. Shanghai and the Yellow Medicine Co., Ltd. R & D Executive Director Zhanchang Sen told reporters that the company and the second-largest, Tsinghua University Cooperation , From 7 herbs pills isolated components of 95 compounds, “peel the first layer of bamboo shoots.” This year, the state “created major new drugs,” science and technology projects will support the company continues to “strip bamboo”, with its life-saving modern medical language crack the password. With the “peeling bamboo shoots” in depth, next year, HMP sales expected to exceed 500 million yuan, among the single-product sales of our proprietary list forefront.
How to get more creative potential release to the market faster, no doubt the decision of the Shanghai Chinese pharmaceutical industry in the future. It is reported that the city authorities are developing the “Shanghai Biological Medicine Industry Development Action Plan (2009-2012)”, outlines the distribution of R & D and industrial base, drawing bigger and stronger focus areas and product road map. At the same time, including government procurement, tax incentives, introduction of talent, including a series of industry incentives, is also expected to work out.
I am China Hardware Suppliers writer, reports some information about chicken incubator , parrot eggs.
Processing your request, Please wait....
